think 3 presentation plus

Ask the publishers to restore access to 500,000+ books.

Internet Archive Audio

• This Just In
• Grateful Dead
• Old Time Radio
• 78 RPMs and Cylinder Recordings
• Audio Books & Poetry
• Computers, Technology and Science
• Music, Arts & Culture
• News & Public Affairs
• Spirituality & Religion
• Radio News Archive

• Flickr Commons
• Occupy Wall Street Flickr
• NASA Images
• Solar System Collection
• Ames Research Center

• All Software
• Old School Emulation
• MS-DOS Games
• Historical Software
• Classic PC Games
• Software Library
• Kodi Archive and Support File
• Vintage Software
• CD-ROM Software
• CD-ROM Software Library
• Software Sites
• Tucows Software Library
• Shareware CD-ROMs
• Software Capsules Compilation
• CD-ROM Images
• ZX Spectrum
• DOOM Level CD

• Smithsonian Libraries
• FEDLINK (US)
• Lincoln Collection
• American Libraries
• Canadian Libraries
• Universal Library
• Project Gutenberg
• Children's Library
• Biodiversity Heritage Library
• Books by Language
• Additional Collections

• Prelinger Archives
• Democracy Now!
• Occupy Wall Street
• TV NSA Clip Library
• Animation & Cartoons
• Arts & Music
• Computers & Technology
• Cultural & Academic Films
• Ephemeral Films
• Sports Videos
• Videogame Videos
• Youth Media

Search the history of over 866 billion web pages on the Internet.

Mobile Apps

• Wayback Machine (iOS)
• Wayback Machine (Android)

Browser Extensions

Archive-it subscription.

• Explore the Collections
• Build Collections

Save Page Now

Capture a web page as it appears now for use as a trusted citation in the future.

Please enter a valid web address

• Donate Donate icon An illustration of a heart shape

Think Eng presentation PLUS Starter

Bookreader item preview, share or embed this item, flag this item for.

• Graphic Violence
• Explicit Sexual Content
• Hate Speech
• Misinformation/Disinformation
• Marketing/Phishing/Advertising
• Misleading/Inaccurate/Missing Metadata

plus-circle Add Review comment Reviews

3,804 Views

DOWNLOAD OPTIONS

For users with print-disabilities

IN COLLECTIONS

Uploaded by Bunnygamers on November 18, 2021

SIMILAR ITEMS (based on metadata)

• Foreign Language Study & Reference

Sorry, there was a problem.

Download the free Kindle app and start reading Kindle books instantly on your smartphone, tablet, or computer - no Kindle device required .

Read instantly on your browser with Kindle for Web.

Using your mobile phone camera - scan the code below and download the Kindle app.

Image Unavailable

• To view this video download Flash Player

Think Starter Presentation Plus DVD-ROM New Edition

• ISBN-10 1107586410
• ISBN-13 978-1107586413
• Edition New
• Publisher Cambridge University Press
• Publication date August 15, 2016
• Language English
• Dimensions 5.3 x 0.53 x 7.5 inches
• See all details

Product details

• Publisher ‏ : ‎ Cambridge University Press; New edition (August 15, 2016)
• Language ‏ : ‎ English
• ISBN-10 ‏ : ‎ 1107586410
• ISBN-13 ‏ : ‎ 978-1107586413
• Item Weight ‏ : ‎ 3.17 ounces
• Dimensions ‏ : ‎ 5.3 x 0.53 x 7.5 inches

Customer reviews

• 5 star 4 star 3 star 2 star 1 star 5 star 0% 0% 0% 0% 0% 0%
• 5 star 4 star 3 star 2 star 1 star 4 star 0% 0% 0% 0% 0% 0%
• 5 star 4 star 3 star 2 star 1 star 3 star 0% 0% 0% 0% 0% 0%
• 5 star 4 star 3 star 2 star 1 star 2 star 0% 0% 0% 0% 0% 0%
• 5 star 4 star 3 star 2 star 1 star 1 star 0% 0% 0% 0% 0% 0%

Customer Reviews, including Product Star Ratings help customers to learn more about the product and decide whether it is the right product for them.

To calculate the overall star rating and percentage breakdown by star, we don’t use a simple average. Instead, our system considers things like how recent a review is and if the reviewer bought the item on Amazon. It also analyzed reviews to verify trustworthiness.

No customer reviews

• About Amazon
• Investor Relations
• Amazon Devices
• Amazon Science
• Sell products on Amazon
• Sell on Amazon Business
• Sell apps on Amazon
• Become an Affiliate
• Advertise Your Products
• Self-Publish with Us
• Host an Amazon Hub
• › See More Make Money with Us
• Amazon Business Card
• Shop with Points
• Reload Your Balance
• Amazon Currency Converter
• Amazon and COVID-19
• Your Account
• Your Orders
• Shipping Rates & Policies
• Returns & Replacements
• Manage Your Content and Devices

• Conditions of Use
• Privacy Notice
• Consumer Health Data Privacy Disclosure
• Your Ads Privacy Choices

• Скидки дня
• Справка и помощь
• Адрес доставки Идет загрузка... Ошибка: повторите попытку ОК
• Продажи
• Список отслеживания Развернуть список отслеживаемых товаров Идет загрузка... Войдите в систему , чтобы просмотреть свои сведения о пользователе
• Краткий обзор
• Недавно просмотренные
• Ставки/предложения
• Список отслеживания
• История покупок
• Купить опять
• Объявления о товарах
• Сохраненные запросы поиска
• Сохраненные продавцы
• Сообщения
• Развернуть корзину Идет загрузка... Произошла ошибка. Чтобы узнать подробнее, посмотрите корзину.

Product Key Features

• Language English
• Publication Name Think Level 3 Presentation Plus DVD-ROM
• Subject English As a Second Language
• Publication Year 2016
• Type Language Course
• Subject Area Foreign Language Study
• Author Herbert Puchta
• Series Think Ser.
• Format DVD-ROM
• Item Height 0.6 in
• Item Weight 3.2 Oz
• Item Length 7.5 in
• Item Width 5.3 in

Additional Product Features

• Intended Audience English as a Second Language
• Illustrated Yes
• Synopsis Think is a vibrant course designed to engage teenage learners and make them think. Presentation Plus is a complete planning and presentation tool for teachers. It includes Interactive Whiteboard software, fully interactive Student's Book and Workbook, full video and audio content, digital Teacher's Book and Teacher's Resource Book for paper-free lesson planning, online teacher training and a link to the online learning management platform to track student's progress. This version comes on DVD. Presentation Plus is also available in ebook format suitable for iOS and Android., Challenge and inspire your teenage learners to think beyond language. Think is a vibrant course designed to engage teenage learners and make them think. Presentation Plus is a complete planning and presentation tool for teachers. It includes Interactive Whiteboard software, fully interactive Student's Book and Workbook, full video and audio content, digital Teacher's Book and Teacher's Resource Book for paper-free lesson planning, online teacher training and a link to the online learning management platform to track student's progress. This version comes on DVD. Presentation Plus is also available in ebook format suitable for iOS and Android.

Fiction & Think and Grow Rich Nonfiction Books

Cd-rom textbooks, cd-rom fiction & books, think and grow rich hardcover nonfiction books & magazines, fiction & think and grow rich nonfiction books in english, cd-rom textbooks in english.

American Think | Level 3 Presentation Plus DVD-ROM

ISBN: 9781107597600

Course: American Think

Presentation plus dvd-rom (level 3).

Old Edition

Expect Delays of Up to 6 Weeks

American English

Beginner – Upper Intermediate

CEFR: A1-B2

9781107597600 10-digit ISBN: 1107597609

9781107597600 (10-digit ISBN: 1107597609)

Herbert Puchta , Jeff Stranks , Peter Lewis-Jones

• Series Description

Series Key Features

Series video.

• Challenge and inspire your teenage learners with thought-provoking topics.
• Guided writing and speaking build confident productive skills.
• Culture lessons encourage students to talk about life in other countries and how it compares with their own.
• "THiNK Exams" lessons and assessment-style activities prepare students for success at Cambridge English: Key, Preliminary and First.
• Graded Workbook activities and extra ideas in the interleaved Teacher’s Edition are ideal for mixed-ability classes.
• Flexible digital support includes Presentation Plus classroom presentation software, online workbooks and interactive ebooks.

EASY ORDER FORM

PRICES LISTED INCLUDE CONSUMPTION TAX

Price Before Tax:

¥10,000   ¥8,000 ∼ 20% OFF!

Let's Go 5th Edition Teacher's Set Campaign

Congratulations! You're eligible to receive 1 free Teacher's Set for of Let's Go 5th Edition ! Click OK to add the free Teacher's Set to your order for no additional cost. Click CANCEL if you do not wish to take advantage of this campaign offer. By clicking OK, you agree to your name and contact details being submitted to the publisher, Oxford University Press.

Please type the number of copies

• Allergy & Immunology
• Anesthesiology
• Critical Care
• Dermatology
• Diabetes & Endocrinology
• Emergency Medicine
• Family Medicine
• Gastroenterology
• General Surgery
• Hematology - Oncology
• Hospital Medicine
• Infectious Diseases
• Internal Medicine
• Multispecialty
• Ob/Gyn & Women's Health
• Ophthalmology
• Orthopedics
• Pathology & Lab Medicine
• Plastic Surgery
• Public Health
• Pulmonary Medicine
• Rheumatology
• Transplantation
• Today on Medscape
• Business of Medicine
• Medical Lifestyle
• Science & Technology
• Medical Students
• Pharmacists

Renewed Hope in Advanced Anal Cancer With ICI-Chemo Combo

Liam Davenport

September 16, 2024

BARCELONA, Spain — Adding retifanlimab, an anti–programmed cell death 1 (PD-1) monoclonal antibody, to carboplatin plus paclitaxel in inoperable locally recurrent or metastatic squamous cell carcinoma (SCC) of the anal canal markedly improves survival outcomes, findings from the POD1UM-303 trial showed.

The research, presented at the European Society for Medical Oncology (ESMO) Annual Meeting 2024 , is the first randomized phase 3 trial of an immune checkpoint in this disease, said lead researcher Sheela Rao, MD, Gastrointestinal and Lymphoma Units, The Royal Marsden NHS Foundation Trust, London, England.

The trial demonstrated the benefit of adding retifanlimab to standard-of-care chemotherapy in this population, Rao continued, with a significant 37% increase in progression-free survival and a trend for a significant 30% overall survival benefit.

With the treatment "generally well tolerated," and the safety profile consistent with other chemotherapy plus checkpoint inhibitor regimens, Rao believes that the combination of retifanlimab and carboplatin-paclitaxel "represents a potential new reference treatment and standard of care" for these patients.

This is "a disease with a high unmet medical need," she said. It's considered an "orphan disease," even though the incidence is increasing by approximately 3% a year due to the endemic presence of human papillomavirus, the primary cause of SCC of the anal canal. HIV infection amplifies the risk and is linked to a 25- to 35-fold increase in incidence, she reported.

Current Standard of Care

Andrés Cervantes, MD, PhD, president of ESMO and professor of medicine at the University of Valencia, Valencia, Spain, who was not involved in the study, told a press conference that the study is "very important" because anal cancer is a notable cause of disease.

The current standard-of-care curative treatment for SCC of the anal canal is chemoradiotherapy, Cervantes told Medscape Medical News . For many years, patients underwent radiation therapy concurrently with mitomycin, which was developed in the 1970s, plus fluorouracil.

More recently, the InterAACT trial, also led by Rao, demonstrated that carboplatin plus paclitaxel was associated with less toxicity and longer survival than cisplatin plus fluorouracil in chemotherapy-naive patients with advanced anal cancer.

This regimen is now the preferred first-line therapy for stage IV anal cancer in the current ESMO Clinical Practice Guidelines for the disease, Cervantes explained.

Nevertheless, "more than one third of patients will eventually relapse — local, regionally, or with distant disease — and there are a lot of patients presenting in a noncurative status with disseminated disease," he noted.

"So far, chemotherapy is only providing palliative symptom control," he continued, "so the addition of immunotherapy [here] is improving outcomes."

The New Data

Following the InterAACT trial, the phase 2 POD1UM-202 trial, also led by Rao, established that retifanlimab had antitumor activity in platinum-refractory patients. Rao and her colleagues combined the two approaches in the current phase 3 study.

In the latest study, patients with locally recurrent or metastatic SCC of the anal canal, who had received no prior chemotherapy, apart from as radiosensitizing or (neo)adjuvant therapy for at least 6 months, were randomized to retifanlimab (n = 154) or placebo (n = 154) for 12 months. Both the groups received standard-dose carboplatin-paclitaxel for 6 months.

After 12 months, 69 patients in the placebo arm who had progressive disease crossed over to the retifanlimab arm.

The two study groups were well matched. The median age was approximately 61 years, and around 67% were women. Approximately 70% patients had received prior radiotherapy, and about 90% had PD-L1 tumor expression. Just over 80% had metastatic disease.

Retifanlimab plus standard chemotherapy was associated with a progression-free survival of 9.3 months vs 7.4 months with placebo plus chemotherapy (hazard ratio [HR], 0.63; P = .0006).

The interim overall survival analysis indicated that patients in the experimental vs placebo arm had a median overall survival of 29.2 vs 23 months, respectively (HR, 0.70; P = .0273). When adjusting for crossover, the benefit was slightly lower (HR, 0.63; P = .0055). The overall survival findings, however, are immature.

In addition, the overall response rate was higher with retifanlimab and carboplatin-paclitaxel at 56% vs 44% with placebo and carboplatin-paclitaxel ( P = .0129), and the median duration of response was 14.0 vs 7.2 months, respectively.

Grade 3 or higher treatment-emergent adverse events were more common with the novel combination, occurring in 83.1% vs 75.0% (placebo). There were four deaths in the retifanlimab arm vs one death in the placebo arm.

As expected, immune-related adverse events were seen more often in the immunotherapy-treated patients, at 46.1% vs 23.7% in the chemotherapy only–treated patients, and adverse events leading to discontinuation occurred in 11.0% vs 2.6% patients, respectively.

The most common grade 3 or higher adverse events across the two groups were neutropenia (32.4%), anemia (19.9%), and a reduced neutrophil count (12.7%).

'A Very Significant Finding'

"This is not only the first immunotherapy randomized trial, it's the first phase three randomized trial in this disease…so I think it's is a very significant finding," said Cervantes.

Dominik P. Modest, MD, from the Department of Hematology, Oncology and Cancer Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, who was not involved in the study, believes that based on the current findings, carboplatin-paclitaxel and retifanlimab should be considered a new standard of care in advanced/metastatic SCC of the anal canal.

The benefit is underlined by the "consistent efficacy data in secondary endpoints," and that the gain is "greater than expected based on monotherapy with checkpoint inhibitors in pretreated patients," added Modest.

Modest highlighted that there was a 45% crossover from the placebo arm to the retifanlimab arm during the follow-up.

This did not, however, have an impact on overall survival, and he speculated this may be because the late introduction of checkpoint inhibition in SCC in anal cancer may not offer a substantial benefit, which may have implications for treatment sequencing.

Modest said he would like to see more information on the efficacy of the triplet combination in clinical subgroups and when stratified by PD-L1 expression, as well as mature overall survival results.

Data from trials such as EA2176 , which is looking at carboplatin plus paclitaxel with nivolumab ( Opdivo ) or placebo, could also have a bearing on how the current study results are viewed, said Modest.

The study was funded by Incyte Corporation. Rao declared advisory roles with Bayer, Hookipa, BeiGene, AstraZeneca, Merck Serono, Seagen, Servier, and Boehringer. Modest declared relationships with Servier, Amgen, Merck, Sanofi, BMS, MSD, AstraZeneca, Pierre Fabre, GSK, Seagen, G1, IKF GmbH, Onkowissen, COR2ED, Taiho, Takeda, Incyte, Cureteq, 21up, MedscapeMedical News, Aptitude Health, and Regeneron. Cervantes declared relationships with AbbVie, Amgen, AnHeart Therapeutics, Foundation Medicine, GSK, Merck Serono, Roche, Transgene, Actuate Therapeutic, Adaptimmune, Affimed, Amcure, Astellas Pharma, AstraZeneca, Bayer, BeiGene, BMS, F-star Therapeutics, FibroGen, Genentech, Gilead, Janssen, Lilly, MedImmune, Natera, Novartis, Ribon Therapeutics, Seamless, Servier, Sierra Oncology, and Takeda.

Send comments and news tips to [email protected] .

TOP PICKS FOR YOU

• Perspective
• Drugs & Diseases
• Global Coverage
• Additional Resources
• Colorectal Cancer Screening: How to Increase Rates
• Prevalence of IBD in Canada May Increase 37% by 2035
• Breast Cancer Exacts High Financial Toll Worldwide
• Diseases & Conditions Hereditary Nonpolyposis Colorectal Cancer
• Fast Five Quiz: Are You Up to Date on Colorectal Cancer Screening Guidance?
• Diseases & Conditions Colorectal Cancer Guidelines
• In Colorectal Cancer, Donating Half a Liver Could Save Lives
• Colorectal Cancer Guidelines
• Hereditary Nonpolyposis Colorectal Cancer
• Colorectal Cancer and KRAS/BRAF
• Colorectal Tumors in Adolescents and Young Adults
• Targeted Treatment in Metastatic Colorectal Cancer
• Current and Emerging Therapies in Refractory Metastatic Colorectal Cancer
• Anal Cancer: The Fundamentals
• Colorectal Cancer On the Rise in Young Adults
• Aspirin Use Enhances Immunosurveillance in Colorectal Cancer
• Targeted Colorectal Cancer Combo Improves QoL

Coursebooks

American Think 2 Presentation Plus

Challenge and inspire your teenage learners to think beyond language. American Think is a fresh, vibrant and upbeat course designed to engage teenage learners and make them think. Presentation Plus Level 2 is a complete lesson planning and presentation tool for teachers. It includes Interactive Whiteboard software, fully interactive Student's Book and Workbook, full video and audio content, digital Teacher's Book and Teacher's Resource Book for paper-free lesson planning, online teacher training and a link to the online learning management platform to track student's progress. This version comes on DVD. Presentation Plus is also available as a mobile application suitable for iOS and Android.